Meda’s rights issue fully subscribed

Not for release, publication or distribution, directly or indirectly, in or into
the United States, Canada, Australia, Japan, Hong Kong, New Zealand, South
Africa or any other jurisdiction where such distribution of this press release
would be subject to legal restrictions

The result of Meda AB’s rights issue, for which the subscription period ended on
4 December 2014, indicates that approximately 33.1 million shares, representing
approximately 99.7 percent of the offered shares, were subscribed for by the
exercise of subscription rights. In addition, subscription forms for
subscription without subscription rights, corresponding to approximately 47.4
million shares and to approximately 142.6 percent of the offered shares, have
been received. Thus, the rights issue is fully subscribed. Through the rights
issue, Meda will receive proceeds amounting to approximately SEK 2,027 million
before issue expenses.

Those who have subscribed for shares without subscription rights will be
allotted shares according to the principles described in the prospectus. Such
subscribers who have been allotted shares without preferential rights are
expected to be notified on 11 December 2014. Only those who are allotted shares
will be notified.

Through the rights issue, Meda’s share capital increases by SEK 33,224,306, from
SEK 332,243,065 to SEK 365,467,371, and the total number of shares increases by
33,224,306, from 332,243,065 to 365,467,371. The new shares subscribed for with
subscription rights are expected to be registered at the Swedish Companies
Registration Office on or about 11 December 2014. Shares subscribed for without
subscription rights are expected to be registered at the Swedish Companies
Registration Office on or about 17 December 2014.

The final day for trading in paid subscribed shares (BTAs) is expected to be on
17 December 2014. The new shares are expected to start trading on Nasdaq
Stockholm on 19 December 2014.

Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank AB (publ) and SEB
Corporate Finance, Skandinaviska Enskilda Banken AB (publ) are acting as
financial advisors and Advokatfirman Lindahl KB is acting as legal advisor to
Meda in connection with the rights issue.

For further inquiries, please contact:

Paula Treutiger, VP Corporate Communications & Sustainability
                      ph: +46 733-666 599


                                  paula.treutiger@meda.se

Meda AB discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication on December 10, 2014, at 10:00 CET.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in more than 150 countries worldwide and the company is
represented by its own organizations in over 60 countries. The Meda share is
listed under Large Cap on Nasdaq Stockholm. Find out more, visit www.meda.se.

Important information

The information in this press release does not constitute an offer to acquire,
subscribe for or otherwise trade in shares, subscription rights or other
securities in Meda. Any invitation to the persons concerned to subscribe for
shares in Meda will only be made through the prospectus which was published by
Meda on 14 November 2014.

This press release may not be released, published or distributed, directly or
indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan,
New Zealand, South Africa or any other jurisdiction where such action is wholly
or partially subject to legal restrictions or where such action would require
additional prospectuses, registrations or other actions in addition to what
follows from Swedish, Danish or English law. Nor may the information in this
press release be forwarded, reproduced or disclosed in a manner that contravenes
such restrictions or would entail such requirements. Failure to comply with this
instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be
registered under the U.S. Securities Act of 1933, as amended, (“Securities Act”)
or securities legislation in any state or other jurisdiction in the United
States and may not be offered or sold, directly or indirectly, in or into the
United States, except pursuant to an available exemption from the registration
requirements of the Securities Act and in compliance with the securities laws of
any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect Meda’s
current view on future events and financial and operational development. The
words “intend”, “estimate”, “expect”, “may”, “plan”, “anticipate” or similar
expressions regarding indications or predictions of future developments or
trends and which are not statements based on historical facts constitute forward
-looking information. Although Meda believes that these statements are based on
reasonable assumptions and expectations, Meda cannot give any assurances that
such statements will materialize. Forward-looking statements are in its nature
involved with both known and unknown risks and uncertainties, since it is
depending on future events and circumstances. Forward-looking statements do not
constitute any representations and warranties and the outcome could differ
materially from the information set out in the forward-looking statements.